US Patent

US12357602 — Compositions comprising encapsulated tretinoin

Method of Use · Assigned to Mayne Pharma LLC · Expires 2038-07-12 · 12y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compositions containing microcapsules less than 50 micrometers in size that encapsulate tretinoin and methods of using them.

USPTO Abstract

The present application is directed to compositions comprising microcapsules comprising encapsulated tretinoin, wherein the microcapsule size is less than 50 Î¼m; and to methods of use thereof.

Drugs covered by this patent

Benzamycin (BENZOYL PEROXIDE) · Mayne Pharma

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3987`	—	Benzamycin

Patent Metadata

Patent number: US12357602
Jurisdiction: US
Classification: Method of Use
Expires: 2038-07-12
Drug substance claim: No
Drug product claim: Yes
Assignee: Mayne Pharma LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.